Lung FibrosisNCT07088185
Pulmonary Outcomes on Patients With Lung Fibrosis
A study testing Routine medical care and Pulmonary rehabilitation in people with Lung Fibrosis, run by South Valley University at 1 site in Egypt.
Trial summary
The pulmonary fibrosis is lung disease that occurs when lung tissue become damaged and scarred. The objectives of treatment are to improve symptoms and quality of life, and slow disease progression. Read more about this study
- Who is it for?
- Ages 35 to 55 years
- Conditions the study is for
- Lung Fibrosis
- What is being tested?
- Routine medical care and Pulmonary rehabilitation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Dec 2024to 1 Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- both gender.
- patients with cystic fibrosis.
Who cannot join
- severe chronic disorders.
- heart failure
- respiratory failure.
- age less than 35 or older than 55 years old.
Trial locations and contacts
1 site in 1 country.
About this study
The pulmonary fibrosis is lung disease that occurs when lung tissue become damaged and scarred. The objectives of treatment are to improve symptoms and quality of life, and slow disease progression.
Read the detailed description
This study will include 60 patients with pulmonary fibrosis from both gender who are aged from 35 - 55 years old.This study will be randomized controlled trial.
- Conditions
- Lung Fibrosis
- Being tested
- Routine medical care, Pulmonary rehabilitation
- Keywords
- Pulmonary outcomes, Lung fibrosis
- Medical subject headings
- Pulmonary Fibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Routine medical careOther
Routine medical care
Pulmonary rehabilitationOther
Pulmonary rehabilitation ( breathing exercises, posture drainage, additive techniques with postural drainage like vibration,shaking and percussion, active cycle of breathing techniques, autogenic drainage) plus routine care.
| Study group | Role | What they receive |
|---|---|---|
| Control group | Other | This group will recieve only routine medical care. Receives: Other: Routine medical care |
| Pulmonary rehabilitation group | Other | Pulmonary rehabilitation ( breathing exercises, posture drainage, additive techniques with postural drainage like vibration,shaking and percussion, active cycle of breathing techniques, autogenic drainage) plus routine medical care. Receives: Other: Routine medical care; Other: Pulmonary rehabilitation |
What is being measured
The primary outcome is the main question the study is designed to answer.
FVC
Forced vital capacity (FVC).
Measured: One month
FEV1
Forced expiratory volume in the first second (FEV1)
Measured: One month
The FEV1 on FVC
The ratio between FEV1 and FVC
Measured: One month.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2025
- Study start1 Dec 2024
- Primary completion1 May 2026 (estimated)
- Study completion1 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung FibrosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- South Valley University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shymaa yussuf abo zaid, South Valley University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07088185
- Sponsor's protocol ID
- P.T_INT_11/2024_554
- Status last verified
- Jul 2025
- First submitted
- 17 Jun 2025
- Last updated
- 28 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: I will not share it outside the primary research group.
Study at a glance
From the registry record, last updated by the sponsor on 28 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pulmonary Outcomes on Patients With Lung Fibrosis
- ClinicalTrials.gov ID
- NCT07088185
- Acronym / sponsor ID
- P.T_INT_11/2024_554
- Conditions
- Lung Fibrosis
- Keywords
- Pulmonary outcomes, Lung fibrosis
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- South Valley UniversityUniversity, hospital or other
- Study start
- 1 Dec 2024 (actual)
- Primary completion
- 1 May 2026 (estimated)
- Study completion
- 1 Aug 2026 (estimated)
- First posted
- 28 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The pulmonary fibrosis is lung disease that occurs when lung tissue become damaged and scarred. The objectives of treatment are to improve symptoms and quality of life, and slow disease progression.
Detailed description
This study will include 60 patients with pulmonary fibrosis from both gender who are aged from 35 - 55 years old.This study will be randomized controlled trial.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control group | Other | Other: Routine medical careThis group will recieve only routine medical care. |
| Pulmonary rehabilitation group | Other | Other: Routine medical care, Other: Pulmonary rehabilitationPulmonary rehabilitation ( breathing exercises, posture drainage, additive techniques with postural drainage like vibration,shaking and percussion, active cycle of breathing techniques, autogenic drainage) plus routine medical care. |
Who may qualify
- Ages
- 35 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- both gender.
- patients with cystic fibrosis.
Key exclusion criteria (4 listed)
- severe chronic disorders.
- heart failure
- respiratory failure.
- age less than 35 or older than 55 years old.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Routine medical careRoutine medical care | Other | Control group, Pulmonary rehabilitation group |
| Pulmonary rehabilitationPulmonary rehabilitation ( breathing exercises, posture drainage, additive techniques with postural drainage like vibration,shaking and percussion, active cycle of breathing techniques, autogenic drainage) plus routine care. | Other | Pulmonary rehabilitation group |
Primary outcome
FVC
Time frame: One month
Forced vital capacity (FVC).
FEV1
Time frame: One month
Forced expiratory volume in the first second (FEV1)
The FEV1 on FVC
Time frame: One month.
The ratio between FEV1 and FVC
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jul 2025.
- Individual participant dataSharing planned: No. I will not share it outside the primary research group.
Related trials for Lung Fibrosis
Active, not recruitingObservational study
CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis
Cystic Fibrosis, Bone Loss
RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
RecruitingObservational study
Natural History of Bronchiectasis
Bronchiectasis, Cystic Fibrosis
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Routine medical care and Pulmonary rehabilitation in people with Lung Fibrosis, run by South Valley University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 28 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
FVC (time frame: One month). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2025.